koncentrat til injektions-/infusionsvæske

DRUG2 trials

Sponsors

F. Hoffmann-La Roche AG, Vall D Hebron Institute Of Oncology

Conditions

Advanced selected solid tumors: melanomaChronic Lymphocytic Leukemia (CLL)non-small cell lung cancer (NSCLC) and cervical cancer.

Phase 2

Phase II randomized study evaluating a Pragmatic approach to Adoptive Cell Therapy (ACT) using an IL2 analog (ANV419) vs High dose IL2 after Tumor Infiltrating Lymphocytes (TIL) Therapy in patients with melanoma, NSCLC and cervical cancer. The PragmaTIL

RecruitingCTIS2023-506400-99-00

Vall D Hebron Institute Of OncologyAdvanced selected solid tumors: melanoma, non-small cell lung cancer (NSCLC) and cervical cancer.

Start: 2025-01-15Target: 24Updated: 2025-12-02

Phase 3

A Prospective, Open-Label, Multicenter Randomized Phase III Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine and Rituximab (BR) in FIT Patients with previously untreated Chronic Lymphocytic Leukemia (CLL) without DEL(17P) or TP53 Mutation

CompletedCTIS2023-504036-17-00

F. Hoffmann-La Roche AGChronic Lymphocytic Leukemia (CLL)

Start: 2020-05-07End: 2025-03-18Target: 121Updated: 2025-04-17